オプションチェーンは、Bioteの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Bioteの市場センチメントを評価します。.

Biote (NASDAQ:BTMD) 株価情報, オプションチェーン

Biote

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.

Biote Corp

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 10 years by 2.98% on an annualized basis producing an average annual return of 13.47%. Currently, Agnico Eagle Mines has a market capitalization of $55.88 billion. 
Buying $100 In AEM: If an investor had bought $100 of AEM stock 10 years ago, it would be worth $362.54 today based on a price of $111.15 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746227716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

UBS analyst Andrew Spinola maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Neutral and lowers the price target from $11.5 to $11.

Price Target

Analyst Ratings

VIAV

UBS Maintains Neutral on Viavi Solutions, Lowers Price Target to $11

UBS analyst Taylor McGinnis maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Buy and lowers the price target from $175 to $150.

TWLO

UBS Maintains Buy on Twilio, Lowers Price Target to $150

UBS analyst Karl Keirstead maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Neutral and lowers the price target from $230 to $215.

TEAM

UBS Maintains Neutral on Atlassian, Lowers Price Target to $215

UBS analyst A.J. Rice maintains Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) with a Buy and lowers the price target from $90 to $88.

UBS Maintains Buy on Service Corp Intl, Lowers Price Target to $88

UBS analyst Seth Gilbert maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $32 to $28.

OTEX

UBS Maintains Neutral on Open Text, Lowers Price Target to $28

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

UBS analyst Peter Grom maintains Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) with a Neutral and lowers the price target from $15 to $13.5.

UBS Maintains Neutral on Utz Brands, Lowers Price Target to $13.5

UBS analyst Peter Grom maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $175 to $170.

UBS Maintains Neutral on Hershey, Lowers Price Target to $170

UBS analyst Joseph Spak maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Neutral and lowers the price target from $51 to $50.

UBS Maintains Neutral on General Motors, Lowers Price Target to $50

UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and lowers the price target from $22 to $19.

FRSH

UBS Maintains Buy on Freshworks, Lowers Price Target to $19

UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Neutral and lowers the price target from $47 to $41.

CYTK

UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41

UBS analyst Taylor McGinnis maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and lowers the price target from $55 to $35.

FIVN

UBS Maintains Buy on Five9, Lowers Price Target to $35

UBS analyst Damian Karas maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $56 to $53.

CGNX

UBS Maintains Buy on Cognex, Lowers Price Target to $53

UBS analyst Peter Grom maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Neutral and lowers the price target from $110 to $102.

UBS Maintains Neutral on Church & Dwight Co, Lowers Price Target to $102

UBS analyst John Lovallo maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and lowers the price target from $180 to $163.

BLDR

UBS Maintains Buy on Builders FirstSource, Lowers Price Target to $163

UBS analyst Joshua Spector maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and lowers the price target from $335 to $324.

UBS Maintains Buy on Air Products & Chemicals, Lowers Price Target to $324

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and lowers the price target from $355 to $310.

UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310

UBS analyst Trung Huynh maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and lowers the price target from $319 to $315.

AMGN

UBS Maintains Neutral on Amgen, Lowers Price Target to $315

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 8.33% on an annualized basis producing an average annual return of 22.97%. Currently, Devon Energy has a market capitalization of $20.23 billion. 
Buying $100 In DVN: If an investor had bought $100 of DVN stock 5 years ago, it would be worth $275.31 today based on a price of $31.44 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Biote

Biote (BTMD) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル